This study will test the hypothesis that the addition of a nonselective beta-adrenergic blocking agent to standard therapy will reduce mortality in patients with moderate to severe chronic heart failure.Congestive heart failure is a major public health problem in the United States. This syndrome affects about 1% of the United States population. Heart transplantation is severely limited by the number of donors. A practical mechanical replacement seems unlikely in the near future. Therefore, Pharmacological therapy will for the near future remain the chief therapy for the majority of patients.
Showing the most recent 10 out of 693 publications